Compare Adaptive Biotechnologies Corp (ADPT) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Fidelity National Information Servcs Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.84 (market cap $3.33B), while Fidelity National Information Servcs Inc trades at $41.15 (market cap $22.02B). The key difference: Fidelity National Information Servcs Inc is far larger — about 6.6× Adaptive Biotechnologies Corp's market cap, and Fidelity National Information Servcs Inc pays a 3.94% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | FIS | |
|---|---|---|
Market Cap | $3.33B | $22.02B |
Sector | Health | Technology |
52-Week High | $22.37 | $81.94 |
52-Week Low | $10.24 | $37.72 |
Enterprise Value | $3.19B | $42.41B |
Dividend Yield | — | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
FIS trades at $42.6, up 1.91% today, with a bullish technical signal despite mixed moving averages. The company shows improving fundamentals with 2025 revenue of $10.68B and a net income margin of 23.35%, supported by a low P/E of 8. Recent news highlights strategic wins, including partnerships with Frankfurt International Bank and First Commerce Bank for cloud-native banking solutions, reinforcing its competitive positioning in financial technology.
The outlook is positive with a consensus price target of $55.40, implying significant upside. Key opportunities include continued revenue growth and margin expansion, but risks involve a high debt load and macroeconomic pressures on lending markets. Analyst sentiment is strongly bullish with 58% buy ratings, though investors should monitor execution on debt management and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
